跳到正文
原文
STAT Pharma 医药频道· Elizabeth Cooney·· 15 天前AI 评分54

一项新研究显示 evolocumab 在降低心肌梗死风险方面优于 ezetimibe

STAT+: Beyond statins, one drug lowered heart attack risk by 20%

AI 导读

一项基于真实世界证据的新试验显示,注射型 PCSK9 抑制剂 evolocumab 在降低 LDL 胆固醇水平和心肌梗死风险方面优于口服胆固醇吸收抑制剂 ezetimibe。

正文

When statins aren’t enough, other cholesterol-lowering drugs come into play. But which one is most effective?

Cardiologists looking to help their patients reduce the amount of LDL, or “bad,” cholesterol threatening to clog their coronary arteries often consider two long-approved drugs, each acting through a different mechanism delivered by a different route. A new trial based on real-world evidence pitted the injectable PCSK9 inhibitor evolocumab, sold by Amgen as Repatha, against the oral cholesterol absorption inhibitor ezetimibe, now generic but previously sold by Merck as Zetia. 

Repatha was the winner.

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

来源:STAT Pharma 医药频道 · statnews.com